









Markets
/
Stocks
/
nasdaq-glsi
/

Greenwich Lifesciences Inc

GLSI

11.460USD

-0.080-0.69%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

154.40MMarket Cap

LossP/E TTM



Greenwich Lifesciences Inc

11.460

-0.080-0.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

113 / 506

Overall Ranking

216 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

42.000

Target Price

+263.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 101.77.

Fairly Valued

The company’s latest PE is -8.38, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.53M shares, decreasing 3.78% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 269.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.04.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.92, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.92

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.44, which is -8.42% below the recent high of -7.73 and -9.90% above the recent low of -9.27.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Greenwich Lifesciences Inc is 42.00, with a high of 45.00 and a low of 39.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

42.000

Target Price

+263.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Greenwich Lifesciences Inc

GLSI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.68, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 12.83 and the support level at 10.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.68

Change

-0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Neutral

RSI(14)

50.525

Neutral

STOCH(KDJ)(9,3,3)

34.892

Neutral

ATR(14)

0.700

High Vlolatility

CCI(14)

17.806

Neutral

Williams %R

63.900

Sell

TRIX(12,20)

-0.150

Sell

StochRSI(14)

59.977

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

11.420

Buy

MA10

11.331

Buy

MA20

11.441

Buy

MA50

11.536

Sell

MA100

10.581

Buy

MA200

11.174

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 63.79%, representing a quarter-over-quarter decrease of 1.11%. The largest institutional shareholder is The Vanguard, holding a total of 269.00K shares, representing 1.97% of shares outstanding, with 5.66% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Patel (Snehal)

5.57M

+0.33%

McWilliams (David B)

620.33K

Hallock (Kenneth)

397.33K

BlackRock Institutional Trust Company, N.A.

321.62K

-1.81%

Rothe (Eric)

313.25K

The Vanguard Group, Inc.

Star Investors

270.31K

-1.70%

Thompson (Jaye L)

264.14K

+0.38%

Geode Capital Management, L.L.C.

137.01K

+2.19%

Daugherty (Frank Joseph)

90.13K

DIM Funds SICAV S.A.

87.00K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.12, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 3.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.